A novel bimodal lipidic contrast agent for cellular labelling and tumour MRI
A novel bimodal lipidic contrast agent for cellular labelling and tumour MRI
复制标题
DOI：
10.1039/b910561a
复制
发表时间：
2010-01-01
影响因子：
3.2
通讯作者：
Miller, Andrew
中科院分区：
文献类型：
--
作者：
Kamaly, Nazila;Kalber, Tammy;Miller, Andrew
我们已经合成了一个双峰的双分子轴承荧光团和造影剂的签名相同的结构，以创建一个强大的双峰脂质体磁共振成像（MRI）和荧光显微镜的效用。在这种新的顺磁性和荧光脂质的合成中考虑的双模态概念是有价值的，因为可以获得信号的解剖信息（MRI）以及非常灵敏的定位（离体荧光显微术），因此可以获得脂质体生物分布。双峰阳离子和中性PEG化脂质体使用这种新型脂质探针配制，并用于体外标记细胞和体内成像人卵巢异种移植物。中性PEG化脂质体给药后肿瘤信号增强增加超过6倍，并维持在该水平直至24 h终点。我们的研究结果表明，这种脂质是更有效和更敏感的单签名顺磁性脂质Gd，DOTA，DSA在细胞标记和肿瘤MRI。
We have synthesized a bimodal lipidic molecule bearing both fluorophore and contrast agent signatures on the same structure in order to create a robust bimodal liposome for both magnetic resonance imaging (MRI) and fluorescence microscopy utility. The dual-modality concept considered in the synthesis of this new paramagnetic and fluorescent lipid is valuable in that anatomical information (MRI) as well as very sensitive localization (ex vivo fluorescence microscopy) of signal, and therefore liposome biodistribution, is obtainable. Bimodal cationic and neutral PEGylated liposomes were formulated using this novel lipid probe and used to label cells in vitro and image human ovarian xenografts in vivo. Tumour signal enhancement was increased by over 6-fold post-administration of the neutral PEGylated liposomes, and was maintained at this level up to the 24 h end-point. Our results showed this lipid to be more effective and sensitive than the single signature paramagnetic lipid Gd.DOTA.DSA at cellular labelling and tumour MRI.